logo
Plus   Neg
Share
Email

Amgen: ABP 798 Shows Clinical Equivalence To Rituxan In Clinical Study

Amgen (AMGN) and Allergan plc (AGN) said a clinical study demonstrated clinical equivalence of ABP 798 to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. In the study, the overall response rate by week 28 was within the prespecified margin for ABP 798.

Safety and immunogenicity of ABP 798, a biosimilar candidate, were comparable to Rituxan. The comparative clinical study was the second of two studies to support regulatory submissions for ABP 798.

In 2011, Amgen and Allergan plc formed a collaboration to develop and commercialize oncology antibody biosimilar medicines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Auto Workers at General Motors will remain on strike until ratification of a new four-year labor contract, the union said on Thursday. GM's proposed agreement includes an $11,000 ratification bonus to workers, wage increases of 4 percent throughout the four-year contract, no increases in health care costs; and a path to permanent worker status within four years or less. Streaming giant Netflix Inc. (NFLX) announced that it secured rights to Jeff Smith's critically acclaimed comic book series BONE. Netflix said it plans to develop an animated kids series based on BONE that follows the iconic Bone cousins on an adventure through a vast, uncharted desert and into a... Swedish luxury auto maker Volvo Cars unveiled its first fully electric car, the XC40 Recharge. The XC40 Recharge is a part of the electrified car portfolio that Volvo plans to introduce under the new 'Recharge' sub-brand. The company said it plans to launch a fully electric car every year over the...
Follow RTT
>